business / news / / Business Today
Eli Lilly’s value share in the GLP-1 segment declined to about 56% in March.
Semaglutide generics launched after March 2026 patent expiry are eroding Eli Lilly's Mounjaro market share.
KEY POINTS
- Eli Lilly's value share in the GLP-1 segment dropped to 56% in March 2026.
- Over 25 semaglutide brands from more than a dozen companies have entered the Indian market.
- Novo Nordisk cut Ozempic and Wegovy starting dose prices by up to 48% in early 2026.
- Industry estimates suggest semaglutide unit sales could double or triple within a month of generics' launch.
COMPANIES
Summarized by Newsio from Business Today. How we summarize →